These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8538483)

  • 1. Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered.
    Revilla R; Revilla M; Hernández ER; Villa LF; Varela L; Rico H
    Maturitas; 1995 Sep; 22(2):145-50. PubMed ID: 8538483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
    Lindsay PC; Shaw RW; Bennink HJ; Kicovic P
    Fertil Steril; 1996 Feb; 65(2):342-8. PubMed ID: 8566259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total and regional bone mineral content in women treated with GnRH agonists.
    Rico H; Arnanz F; Revilla M; Perera S; Iritia M; Villa LF; Arribas I
    Calcif Tissue Int; 1993 May; 52(5):354-7. PubMed ID: 8504372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
    Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
    Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of endometriosis with the GnRH analog triptorelin with special reference to the effect on bone density].
    Regidor PA; Imberg C; Bühler K; Reiners C; Schindler AE
    Zentralbl Gynakol; 1993; 115(11):473-7. PubMed ID: 8296491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptorelin for the treatment of endometriosis.
    Leone Roberti Maggiore U; Scala C; Remorgida V; Venturini PL; Del Deo F; Torella M; Colacurci N; Salvatore S; Ferrari S; Papaleo E; Candiani M; Ferrero S
    Expert Opin Pharmacother; 2014 Jun; 15(8):1153-79. PubMed ID: 24832495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis.
    Compston JE; Yamaguchi K; Croucher PI; Garrahan NJ; Lindsay PC; Shaw RW
    Bone; 1995 Feb; 16(2):261-7. PubMed ID: 7756056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi.
    Parazzini F; Di Cintio E; Chatenoud L; Moroni S; Ardovino I; Struzziero E; Falsetti L; Bianchi A; Bracco G; Pellegrini A; Bertulessi C; Romanini C; Zupi E; Massobrio M; Guidetti D; Troiano L; Beretta P; Franchi M
    Eur J Obstet Gynecol Reprod Biol; 2000 Jan; 88(1):11-4. PubMed ID: 10659911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
    Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
    Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian suppression treatment prior to in-vitro fertilization and embryo transfer in Chinese women with stage III or IV endometriosis.
    Ma C; Qiao J; Liu P; Chen G
    Int J Gynaecol Obstet; 2008 Feb; 100(2):167-70. PubMed ID: 18029283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosis associated with gonadorelin agonist administration.
    Mahe V; Nartowski J; Montagnon F; Dumaine A; Glück N
    Br J Psychiatry; 1999 Sep; 175():290-1. PubMed ID: 10645342
    [No Abstract]   [Full Text] [Related]  

  • 13. Different effects of agonistic vs. antagonistic gnrh-analogues (triptorelin vs. cetrorelix) on bone modeling and remodeling in peripubertal female rats.
    Roth CL; Neu C; Jarry H; Schoenau E
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):451-6. PubMed ID: 16151979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of triptorelin versus placebo on the symptoms of endometriosis.
    Bergqvist A; Bergh T; Hogström L; Mattsson S; Nordenskjöld F; Rasmussen C
    Fertil Steril; 1998 Apr; 69(4):702-8. PubMed ID: 9548161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in body composition in women treated with gonadotropin-releasing hormone agonists.
    Revilla R; Revilla M; Villa LF; Cortés J; Arribas I; Rico H
    Maturitas; 1998 Nov; 31(1):63-8. PubMed ID: 10091206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometriosis.
    Devogelaer JP; Nagant de Deuxchaisnes C; Donnez J
    Lancet; 1993 Jan; 341(8840):312-3. PubMed ID: 8093956
    [No Abstract]   [Full Text] [Related]  

  • 17. Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis: Post-hoc analysis of a multicentre, prospective, real-world study.
    Sun W; Hua K; Hong L; Zhang J; Hao M; Wang J; Zhang J; Perrot V; Li H; Zhang X
    Medicine (Baltimore); 2021 Jul; 100(30):e26753. PubMed ID: 34397719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of weight and seasonal changes on radiogrammetry and bone densitometry.
    Rico H; Revilla M; Cardenas JL; Villa LF; Fraile E; Martín FJ; Arribas I
    Calcif Tissue Int; 1994 May; 54(5):385-8. PubMed ID: 8062155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
    Moghetti P; Castello R; Zamberlan N; Rossini M; Gatti D; Negri C; Tosi F; Muggeo M; Adami S
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1250-4. PubMed ID: 10199763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.